+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience

Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience

Indian Journal of Cancer 54(1): 197-202

There is limited Indian data on clinical profile and treatment outcomes for patients with Stage IV adenocarcinoma of lung. We aimed to prospectively study the clinical profile and treatment outcomes for patients with Stage IV adenocarcinoma of lung at a tertiary cancer center. One hundred and ninetyfour patients with Stage IV adenocarcinoma of lung were prospectively analyzed for demographic and molecular profile (epidermal growth factor receptor [EGFR] and echinodermal microtubuleassociated proteinlike 4anaplastic lymphoma kinase [EML4ALK] mutations). Patients with EGFR and EML4ALK mutations were treated with tyrosine kinase inhibitors. Patients without these mutations were treated with standard chemotherapy regimens. Maintenance chemotherapy was offered to patients as per standard guidelines. Clinical outcomes measured were response rate (RR), progressionfree survival (PFS), and overall survival (OS). Median age of patients was 56 years (range, 26-82) with a male:female ratio of 2.3:1. EGFR and ALK mutation testing was feasible in 169 (87.1%) and 164 (84.5%), respectively, and detected in 37.9% and 5.5% patients, respectively. Overall RR, PFS and OS of whole cohort were 44.3%, 6.9, and 15.5 months, respectively. PFS and OS of mutated group (EGFR, EML4ALK) were longer than nonmutated group (10.5 vs. 5.4 months, P < 0.0001 and 21.5 vs. 11 months, P = 0.0001, respectively). PFS and OS of patients who received pemetrexed maintenance were longer than those who did not receive maintenance (8.5 vs. 6.5 months, P = 0.1613 and 18.5 vs. 12.5 months, P = 0.0219, respectively). Mutation testing at diagnosis is feasible in the vast majority of patients with Stage IV adenocarcinoma of the lung. Patients with EGFR or EML4ALK mutation and those who received pemetrexed maintenance had better clinical outcomes.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 054870326

Download citation: RISBibTeXText

PMID: 29199690

Related references

Clinical outcome of early-stage endometroid adenocarcinoma: a tertiary cancer center experience. International Journal of Gynecological Cancer 23(8): 1446-1452, 2014

Treatment outcomes in patients with extensive stage small cell lung cancer - Experience from a tertiary Indian cancer centre. Journal of Clinical Oncology 26(15_Suppl): 19129-19129, 2016

Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. Indian Journal of Cancer 55(2): 125-133, 2019

Clinical profile of nonsmall cell lung carcinoma patients treated in a single unit at a tertiary cancer care center. Indian Journal of Cancer 54(1): 193-196, 2018

Self-expandable metal stents (SEMS) can serve as a bridge to surgery or as a definitive therapy in patients with an advanced stage of cancer: clinical experience of a tertiary cancer center. Digestive Diseases and Sciences 55(12): 3530-3536, 2011

Clinical characteristics, staging procedures and pattern of treatment of lung cancer patients managed outside a clinical research protocol The experience of a tertiary oncology center. European Respiratory Journal 8(Suppl. 19): 374S, 1995

Outcomes in Lung Cancer: 9-Year Experience From a Tertiary Cancer Center in India. Journal of Global Oncology 3(5): 459-468, 2017

Video-assisted thoracoscopic surgery and thoracotomy during lobectomy for clinical stage I non-small-cell lung cancer have equivalent oncological outcomes: A single-center experience of 212 consecutive resections. Oncology Letters 9(3): 1364-1372, 2015

First-line therapy outcomes in patients with advanced stage nonsmall cell lung cancer treated at nongovernment tertiary care centrer in India: Experience from a real world practice. Indian Journal of Cancer 54(1): 182-186, 2018

Pregnancy Outcomes After Abdominal Radical Trachelectomy for Early-Stage Cervical Cancer: A 13-Year Experience in a Single Tertiary-Care Center. International Journal of Gynecological Cancer 26(1): 163-168, 2016

Radiologic Predictors for Clinical Stage IA Lung Adenocarcinoma with Ground Glass Components: A Multi-Center Study of Long-Term Outcomes. Plos One 10(9): E0136616, 2016

Surgical outcomes of early-stage small-cell lung cancer: single-center experience. Asian Cardiovascular & Thoracic Annals 2019: 218492319826724-218492319826724, 2019

Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Surgical Oncology 27(4): 619-624, 2018

Preoperative chemoradiotherapy for stage I-III adenocarcinoma of the pancreas The Fox Chase Cancer Center experience with 63 patients. Cancer Bulletin 46(6): 499-503, 1994

Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan. Journal of Ayub Medical College, Abbottabad 28(2): 293-297, 2017